Differences

This shows you the differences between two versions of the page.

--- projects:workgroups:kb-wg [2017/01/03 18:43] – rkboyce
+++ projects:workgroups:kb-wg [2018/09/18 13:14] (current) – [Meetings (Telecon Info)] ericavoss
@@ Line 1: / Line 1: @@
-====== Knowledgebase (LAERTES) Workgroup ======
+====== Pharmacovigilance evidence investigation Workgroup  ======
 <WRAP box justify round>
-**Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. The WG's first contribution to OHDSI will be LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates numerous sources of evidence useful for investigating the association of drugs and health into a single system. The system will extend the OHDSI Standard Vocabulary and provide for summary and drill down evidence review use cases. The first release of LAERTES is schedule for April 2015
+**Objective:** The objective of this workgroup (WG) is to establish an open-source standardized knowledge base for the effects of medical products and an efficient procedure for maintaining and expanding it. For a complete overview, please see the paper [[http://www.ncbi.nlm.nih.gov/pubmed/24985530|Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest]]. In 2015/16 the WG contributed LAERTES (Largescale Adverse Effects Related to Treatment Evidence Standardization) -- a system that integrates several sources of evidence investigating the association of drugs and health into a single system. The first staging release of LAERTES occurred last year and is reported in https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3.
-**Project Lead:**  [[http://ohdsi.org/who-we-are/collaborators/richard-d-boyce-2/|Richard D. Boyce, PhD]]
+One of the primary use cases for the WG has been the creation of negative controls. Members of the WG published a paper reporting on the accuracy of automated negative control generation using machine learning and the merged evidence base: http://dx.doi.org/10.1016/j.jbi.2016.12.005
-**Project Co-Lead:** [[http://ohdsi.org/who-we-are/collaborators/erica-voss/|Erica Voss, MPH]]
+The current efforts of the WG are focused on improving the process of creating and maintaining the merged evidence base, providing better support in OHDSI tools for negative control generation, and developing user friendly methods for using the merged evidence base to investigate pharmacovigilance signals. Other use cases are also being discussed. The new merged evidence base is called the Common Evidence Model and is accessible by requesting data from the project leads. The WG plans to make the data accessible from the OHDSI Web API by April 2018 (see https://goo.gl/1m6NcB).
-**Members:**
+**Project Lead:** [[http://ohdsi.org/who-we-are/collaborators/erica-voss/|Erica Voss, MPH]]
-See [[kb-wg#internal|Members List]] but note that active membership is completely voluntary and open.
+**Project Co-Lead:**  [[http://ohdsi.org/who-we-are/collaborators/richard-d-boyce-2/|Richard D. Boyce, PhD]]
+**Members:**
 **Start Date:** 6/10/2014
-**Repository:**  [[https://github.com/OHDSI/KnowledgeBase]]
+**Repository:**  [[https://github.com/OHDSI/CommonEvidenceModel]]
-**WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|Knowledge Base WG Minutes]]
+**WG Minutes:** [[https://docs.google.com/document/d/1T3TlmtkCL0BCNMJAUY76h4EV2mapEMAclaRFgmY_zzE/edit?usp=drive_web|WG Minutes]]
-**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172|Knowledge Base WG Agendas]]
+**WG Agendas:** [[http://forums.ohdsi.org/t/laertes-team-meeting-agenda/172| WG Agendas]]
 **Publications:**
-Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/s40264-014-0189-0, PubMed PMID: 24985530. PMCID: PMC4134480. http://link.springer.com/article/10.1007%2Fs40264-014-0189-0
 E.A. Voss, R.D. Boyce, P.B. Ryan, J. van der Lei, P.R. Rijnbeek, M.J. Schuemie, Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions, Journal of Biomedical Informatics, Available online 16 December 2016, ISSN 1532-0464, http://dx.doi.org/10.1016/j.jbi.2016.12.005.
-Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M.,  Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. LAERTES: An open system architecture for linking pharmacovigilance evidence sources with clinical data. Journal of Biomedical Semantics. Accepted on 1/3/2017. In Process.
+Boyce, RD., Voss, E., Huser, V., Evans, L., Reich, C., Duke, JD., Tatonetti, NP., Lorberbaum, T., Dumontier, M., Hauben, M., Wallberg, M., Peng, L., Dempster, S., He, O., Sena, A., Koutkias, V., Natsiavas, P., Ryan, P. (Knowledge Base workgroup of the Observational Health Data Sciences and Informatics (OHDSI) collaborative). Large-scale adverse effects related to treatment evidence standardization (LAERTES): an open scalable system for linking pharmacovigilance evidence sources with clinical data. J Biomed Semantics. 2017 Mar 7;8(1):11. doi: 10.1186/s13326-017-0115-3. Available at: https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-017-0115-3. PubMed PMID: 28270198; PubMed Central PMCID: PMC5341176.
+Boyce. RD., Ryan. PB., Noren. N., et al., Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 2014. Volume 37, Issue 8 (2014), Page 557-567. DOI: 10.1007/s40264-014-0189-0, PubMed PMID: 24985530. PMCID: PMC4134480. http://link.springer.com/article/10.1007%2Fs40264-014-0189-0
@@ Line 34: / Line 37: @@
 ==== Meetings (Telecon Info) ====
-    Schedule: Once per month schedule:
+    Schedule:
+    - All team call once per month on the 4th Wednesday of each month at 9-10 Eastern.
+    - Touch point call on the 2nd Wednesday of each month 9-10 Eastern
-Dec - Tuesday 13th at 3pm Eastern
+Please join the [[https://meet.lync.com/jnj-its/evoss3/Q7P48H1D|Skype Meeting]]
-Jan - Tues 10th at 3pm Eastern
+Trouble Joining? [[https://meet.lync.com/jnj-its/evoss3/Q7P48H1D?sl=1|Try Skype Web App]]
-Feb - Tues 6th at 3pm Eastern
+Toll number: +1 (908) 316-2436,,89194944# (Dial-in Number)
+[[https://dialin.lync.com/6071d915-71cb-44a6-ae05-d1830c6bbb14?id=89194944|Find a Local Number]]
-    Please join my meeting.
+HOW TO JOIN SKYPE MEETING AUDIO
-    https://global.gotomeeting.com/join/530277469
+. "Use Skype for Business (full audio and video experience)" Select ONLY if you are using a USB connected Audio Device and have a good network connection (DO NOT SELECT THIS OPTION IF YOU ARE DIALING IN FROM A PHONE)
+. "Call Me at" Select if you have a phone that can be directly dialed (not supported in all countries).
+."Don't join audio" Select if you will be dialing into the meeting from your phone.
+IMPORTANT NOTICE: Please note that Skype For Business Meetings allow the audio and other information sent during the session to be recorded, which may be discoverable in a legal matter. By joining this session, you automatically consent to such recordings. If you do not consent to being recorded, discuss your concerns with the host or do not join the meeting.
-    Use your microphone and speakers (VoIP) - a headset is recommended.
-    Or, call in using your telephone:
-    United States: +1 (224) 501-3217
-    Sweden: +46 (0) 853 527 836
-    Access Code: 530-277-469
 === Discussions ===
@@ Line 62: / Line 68: @@
 === GitHub Issues ===
-[[https://github.com/OHDSI/KnowledgeBase/issues]]
+[[https://github.com/OHDSI/CommonEvidenceModel/issues]]
-=== Members List ===
-Richard D. Boyce, University of Pittsburgh, Pittsburgh, PA, [email protected]
+=== Active members List (add or delete your name if you see an omission or error) ===
 Erica A. Voss, Janssen Research & Development, LLC, Titusville, NJ, [email protected]
-Vojtech Huser, National Institutes of Health, Bethesda, MD, vojtech.huser@nih.gov
+Richard D. Boyce, University of Pittsburgh, Pittsburgh, PA, rdb20@pitt.edu
 Lee Evans, LTS Computing LLC, West Chester, PA, [email protected]
-Christian Reich, QuintilesIMS, Burlington MA, [email protected]
-Jon D. Duke, Georgia Tech Research Institute, Atlanta, GA, [email protected]
-Nicholas P. Tatonetti, Herbert Irving Assistant Professor of Biomedical Informatics, Columbia University, New York, NY, [email protected]
-Tal Lorberbaum, Columbia University, New York, NY, [email protected]
-Michel Dumontier, Stanford University, Stanford, CA, [email protected]
-Manfred Hauben, MD. MPH, Pfizer Inc, New York University Medical Center,  New York, NY, [email protected]
-Magnus Wallberg, Uppsala Monitoring Centre, Uppsala, Sweden, [email protected]
-Lili Peng, AstraZeneca R&D, Boston , MA, [email protected]
-Sara Dempster, AstraZeneca R&D, Boston , MA, [email protected]
-Yongqun He, University of Michigan Medical School, Ann Arbor, Michigan, [email protected]
 Anthony G. Sena, Janssen Research & Development, LLC, Titusville, NJ, [email protected]
@@ Line 99: / Line 84: @@
 Pantelis Natsiavas, Institute of Applied Biosciences, Center for Research & Technology Hellas, Thermi, Thessaloniki, Greece, [email protected]
+Manfred Hauben, MD. MPH, Pfizer Inc, New York University Medical Center,  New York, NY, [email protected]
 Patrick B. Ryan, Janssen Research & Development, LLC, Titusville, NJ, [email protected]